Berkshire Biomedical Launches Equity Crowdfunding Initiative
Berkshire Biomedical has initiated its first public investment campaign aimed at advancing its innovative COPA™ technology.
Berkshire Biomedical Corporation, dedicated to developing groundbreaking drug dispensing technology that promotes patient wellness, has recently announced an equity crowdfunding campaign. This initiative offers investors a rare opportunity to contribute financially and gain ownership in a company that is determined to transform the landscape of patient-administered medication delivery.
The star of the campaign is the Computerized Oral Prescription Administration System, known as COPA™. This state-of-the-art oral liquid dispensing system is engineered to dispense accurate and precise doses of controlled and non-controlled prescription medications. Each dispense is strictly limited to the Authenticated Intended User (AIU™) through a two-pronged biometric identification process that includes both fingerprint and dental recognition. The principal aim is to elevate patient wellness while enabling effective remote monitoring.
“We are thrilled to launch this equity crowdfunding opportunity, allowing individual investors to join us on our journey,” said John Timberlake, the Chief Executive Officer of Berkshire. “Our mission centers on enhancing patient wellness. We have high hopes that our cloud-based COPA device will significantly increase access to medication for those struggling with Opioid Use Disorder (OUD), which currently only reaches about 20% of the 5.7 million affected individuals. Beyond OUD, we see COPA as a versatile solution for managing other chronic conditions, including chronic pain and central nervous system diseases. By participating in our StartEngine campaign, investors can help shape the future of personalized medication delivery.”
Berkshire's equity crowdfunding campaign is currently live, providing potential investors an exciting chance to engage with and support the company's innovative growth strategies. For more details about the offering, interested parties can visit the relevant pages that outline the terms and structure of the investment opportunities.
About Berkshire Biomedical Corporation
Berkshire Biomedical is an innovative medical device company redefining the medication delivery process through advanced biometric technologies. Their strategy involves leveraging encrypted, HIPAA-compliant cloud systems that facilitate precise and tailored medication dispensing exclusively to the Authenticated Intended User (AIU).
Currently, the company is heavily focused on advancing its lead product, COPA. This efficient, hand-held device is poised to facilitate the delivery of various liquid medications, contingent upon the verification of dual biometric markers.
Upon receiving necessary regulatory approvals, Berkshire Biomedical aims to initially implement COPA to manage the distribution of oral liquid methadone for drug treatment in individuals with Opioid Use Disorder, followed by applications for chronic pain management and treatment of other high-need cases.
The company has garnered substantial support for COPA’s development, including a substantial $2 million Fast-Track Small Business Innovation Research grant awarded by the National Institute of Drug Abuse as part of their commitment to combating the opioid crisis.
As they progress, Berkshire has plans to broaden the scope of COPA to encompass a wider array of therapeutics and clinical applications, particularly in partnership with organizations that leverage data analytics from electronic devices to optimize patient outcomes.
For further insights into Berkshire Biomedical and the COPA System, additional resources can be found through their official communication channels. It is important to note that the COPA System remains under development and has not yet been evaluated by relevant regulatory authorities for commercial distribution.
Contact Information
Berkshire Biomedical Corporation
Melody Carey
Founder, President, and CEO
For inquiries, please reach out via the company's contact platforms.
Frequently Asked Questions
What is the COPA™ technology?
The COPA™ is an innovative computerized oral prescription administration system designed to dispense precise doses of medication to authenticated users.
Why is Berkshire Biomedical launching this crowdfunding campaign?
The campaign aims to empower individual investors to be part of the company's mission to enhance patient wellness through advanced medication delivery technology.
What are the benefits of investing in this initiative?
Investors have a unique opportunity to become stakeholders in a company focused on revolutionary health technology, potentially impacting millions who require effective medication management.
How does COPA ensure safe medication delivery?
The system utilizes dual biometric verification to ensure that only authorized users receive prescribed medications, enhancing safety and accuracy in drug dispensing.
What are the future plans for the COPA system?
Berkshire Biomedical intends to expand COPA's applications beyond opioid treatment to include various chronic pain conditions and a broader range of therapeutics.
